{"?xml":{"@version":"1.0"},"edm:RDF":{"@xmlns:dc":"http://purl.org/dc/elements/1.1/","@xmlns:edm":"http://www.europeana.eu/schemas/edm/","@xmlns:wgs84_pos":"http://www.w3.org/2003/01/geo/wgs84_pos","@xmlns:foaf":"http://xmlns.com/foaf/0.1/","@xmlns:rdaGr2":"http://rdvocab.info/ElementsGr2","@xmlns:oai":"http://www.openarchives.org/OAI/2.0/","@xmlns:owl":"http://www.w3.org/2002/07/owl#","@xmlns:rdf":"http://www.w3.org/1999/02/22-rdf-syntax-ns#","@xmlns:ore":"http://www.openarchives.org/ore/terms/","@xmlns:skos":"http://www.w3.org/2004/02/skos/core#","@xmlns:dcterms":"http://purl.org/dc/terms/","edm:WebResource":[{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-O2T6QA2H/e76ac45c-bf21-4fb6-8aab-e625a83665e8/PDF","dcterms:extent":"208 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-O2T6QA2H/3f2dbd6c-82b4-48fd-ae65-2f77aee4d994/TEXT","dcterms:extent":"30 KB"}],"edm:TimeSpan":{"@rdf:about":"2005-2025","edm:begin":{"@xml:lang":"en","#text":"2005"},"edm:end":{"@xml:lang":"en","#text":"2025"}},"edm:ProvidedCHO":{"@rdf:about":"URN:NBN:SI:doc-O2T6QA2H","dcterms:isPartOf":[{"@rdf:resource":"https://www.dlib.si/details/URN:NBN:SI:spr-8ER5ZBJN"},{"@xml:lang":"sl","#text":"Farmacevtski vestnik"}],"dcterms:issued":"2016","dc:creator":"Kocbek, Petra","dc:format":[{"@xml:lang":"sl","#text":"številka:4"},{"@xml:lang":"sl","#text":"letnik:67"},{"@xml:lang":"sl","#text":"str. 296-302"}],"dc:identifier":["ISSN:0014-8229","COBISSID:4102769","URN:URN:NBN:SI:doc-O2T6QA2H"],"dc:language":"sl","dc:publisher":{"@xml:lang":"sl","#text":"Slovensko farmacevtsko društvo"},"dc:subject":[{"@xml:lang":"sl","#text":"nanodostavni sistemi"},{"@xml:lang":"sl","#text":"nanokristali"},{"@xml:lang":"sl","#text":"nanosuspenzije"},{"@xml:lang":"sl","#text":"Nanotehnologija"},{"@xml:lang":"sl","#text":"razvoj zdravil"},{"@xml:lang":"sl","#text":"težko topne učinkovine"},{"@rdf:resource":"http://www.wikidata.org/entity/Q11468"}],"dcterms:temporal":{"@rdf:resource":"2005-2025"},"dc:title":{"@xml:lang":"sl","#text":"Nanosuspenzije - aktualni nanotehnološki pristop za izdelavo farmacevtskih oblik s težko topnimi učinkovinami?| Nanosuspensions - an up-to-date nanotechnology-based approach for formulation of dosage forms with poorly soluble drugs?|"},"dc:description":[{"@xml:lang":"sl","#text":"Poorly soluble drugs represent a great challenge in all stages of drug development; therefore, the development of new approaches for increasing solubility and dissolution rate is still very popular. Since we live in the era of nanotechnologies, different nanotechnological approaches are particularly interesting, such as preparation of nanosuspensions. The nanosuspensions are the dispersions of nanosized drug particles in a liquid medium and represent a nanodelivery system suitable for any route of administration of poorly soluble drugs in the body. Their advantages, which reflect the nanometer particle size, are higher solubility, higher dissolution rate and better adhesion compared to micrometer sized drug particles. Consequently, biopharmaceutical properties and pharmacological effect are changed. The majority of current research is focused on nanosuspensions for oral use, thus characteristics of oral nanosuspensions and their transformation into patient-friendly solid dosage forms are presented in this paper"},{"@xml:lang":"sl","#text":"Težko topne učinkovine predstavljajo velik izziv v vseh fazah razvoja zdravil, zato so raziskave novih pristopov za povečevanje topnosti in hitrosti raztapljanja še vedno zelo aktualne. Živimo v dobi nanotehnologij, zato so v ospredju zlasti različni nanotehnološki pristopi, kot je izdelava nanosuspenzij. To so disperzije delcev učinkovin nanometrskih velikosti v tekočem mediju in predstavljajo nanodostavni sistem, primeren za vse poti vnosa težko topnih učinkovin v organizem. Njihove prednosti, ki so odraz nanometrske velikosti delcev, so večja topnost, večja hitrost raztapljanja in boljša adhezivnost v primerjavi z delci iste učinkovine mikrometrskih velikosti. Posledično so spremenjene biofarmacevtske lastnosti in farmakološki učinek po vnosu v organizem. Ker so najbolj aktualne raziskave nanosuspenzij za peroralno uporabo, v prispevku predstavljamo njihove značilnosti in pretvorbo v bolniku prijazne trdne farmacevtske oblike"}],"edm:type":"TEXT","dc:type":[{"@xml:lang":"sl","#text":"znanstveno časopisje"},{"@xml:lang":"en","#text":"journals"},{"@rdf:resource":"http://www.wikidata.org/entity/Q361785"}]},"ore:Aggregation":{"@rdf:about":"http://www.dlib.si/?URN=URN:NBN:SI:doc-O2T6QA2H","edm:aggregatedCHO":{"@rdf:resource":"URN:NBN:SI:doc-O2T6QA2H"},"edm:isShownBy":{"@rdf:resource":"http://www.dlib.si/stream/URN:NBN:SI:doc-O2T6QA2H/e76ac45c-bf21-4fb6-8aab-e625a83665e8/PDF"},"edm:rights":{"@rdf:resource":"http://rightsstatements.org/vocab/InC/1.0/"},"edm:provider":"Slovenian National E-content Aggregator","edm:intermediateProvider":{"@xml:lang":"en","#text":"National and University Library of Slovenia"},"edm:dataProvider":{"@xml:lang":"sl","#text":"Slovensko farmacevtsko društvo"},"edm:object":{"@rdf:resource":"http://www.dlib.si/streamdb/URN:NBN:SI:doc-O2T6QA2H/maxi/edm"},"edm:isShownAt":{"@rdf:resource":"http://www.dlib.si/details/URN:NBN:SI:doc-O2T6QA2H"}}}}